Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
But,
LUCY have 180 days from the 4th August to regain NASDAQ compliance, Q1 sales data will be too late.
They'd have to apply for an extension to a Hearings Panel (by submitting a plan of compliance) with no guarantees of acceptance.
Delisting would be a disaster, maybe a trade sale at a knockdown price.
Can't see a Lucy rerate Sea, not without my Smartglasses on! 🤪
They'll be banking on Nautica and Reebok to deliver some sales before they get delisted.
Either that or they've another deal in the pipeline, to prop up the SP.
Cash in the bank is all that's holding the LUCY SP @45 cents.
Oh...and last week; Suzy mixing it with Caroline Austin of AZ (VP, Head of Transactions and Business Development)
http://tinyurl.com/mv9hk5n5
EUDA up 5.98%
EUDAW (W = warrants) up 128.74%
EUDA short interest has declined 67% since last month.
https://www.marketbeat.com/stocks/NASDAQ/EUDAW/sec-filings/
All the market signals are positive. 🤪
Reputation?
This new Board has a good reputation in the industry.
Why do you think that professionals from Kings, Barcelona, Hokkaido, Ambrose, TRX, Stingray and Professor Hargreaves are working with Valirx?
Your post insults their intelligence and your own, in equal measure.
Bleak?
Two billion dollar deals today, in the biotech sector, (Icosavax and Systimmune).
Yet Valirx drops, despite it's carefully managed finances, innovative pipeline of evaluations, P2 assets and a fully functioning laboratory.
The poor reputation of the previous BOD is proving hard to shake off.
Well, fellow Tek investors,
My Amazon Microsalt order should arrive this week.
At the behest of my wife, we use Lo-Salt. It has 66% less sodium, but contains 23% Potassium Chloride, Sodium Chloride, Anti-caking agents (Magnesium Carbonate and Sodium Hexacyanoferrate).
I'll run a taste test with the wife's help and let you know!. 🤪
Porks; I'm bemused as to why your posts are being removed.
Ambrose are a startup with limited funding; that information is in the public domain.
I disagree with your opinions about Valirx (e.g. in my view your obsession with the "cash runway" borders on insanity), but surely you've the right to pass comment on the latest RNS?
LSE - what's happened to freedom of speech?
You guys need to get real, Ambrose are a biotech startup having raised £500,000 (as of April).
The do have a very experienced board:
https://ambrosehc.com/team/
Also plans to IPO in thr Middle East at some point;
https://www.agbi.com/articles/uk-pharma-startup-targets-gulf-for-future-ipo/
It good news, but it won't be blowing the doors off just yet.
Perhaps Flagstaff could explain the £215,000, instead of getting paid for yet another "News Story irrelevant to Microsalt" post.
🙄
Https://tinyurl.com/nztxyuk3
"Oxygen supplementation is one way to help patients who cannot breathe adequately on their own"
Anyone know of a company manufacturing portable oxygen concentrators in China?
🤔
Https://tinyurl.com/2jxpwhut
Although, the piece states "The shares issued for the acquisition may hold back the share price in the short-term and there could be an even better buying opportunity."
Well Lolly, despite the abuse thrown in your direction you've been proven correct about the SP.
Whatever delightful narrative Agricore posts about the aesthetically pleasing glasses, the bottom line is sales are down for the comparable nine months ending 2023 (536,725) vs 2022 (592,720)
The accounts prove Harrison Gross is brilliant at spending dollars on product development, but he can't deliver sales. As has already been posted, a change is needed. Â
Let's see how the US market reacts this afternoon.....
Morning Sea, trying to find the positives is difficult!
They use various excuses, including aggressive discounting from Echo Frames, Rayban etc.
Also: "manufacturing issues with the Lucyd safety glass product line caused this product launch to also be delayed, and is now planned to launch in the second quarter of 2024".
The delisting issue still concerns me. My view remains that they need a deal, partnership or contract to lift the SP.
Https://tinyurl.com/3j5tc8v7
Net loss of $1,551,105
Gross profit of $80,344.
Total value of glasses sold; a mere $221,875.
My initial thoughts are an awful set of results, I'm still wading through the detail. However, they still have close to $4 million in cash.
🫣
Should be titled "P3", sorry.
Imfinzi (durvalumab) failed to meet the primary endpoint of progression free survival in NSCLC.
Sad news for patients, however ;
"A pilot phase II clinical trial showed that VAL401 treatment has a statistically significant improvement in overall survival for patients with late stage non-small cell lung cancer."
https://link.springer.com/article/10.1007/s13318-018-00538-4
I really believe 2024 is going to be a pivotal year for Valirx, IF Suzy can get the funding.
Not long to find out......
Stingray Bio are targeting the LMTK3 kinase, there is a paper on this (from Jan 2023), co-authored by Georgios Giamas (one of Stingray Bio's founders and a director);
https://pubmed.ncbi.nlm.nih.gov/36614307/
In defence of the Board; they were stymied by the incompetent MHRA, for seven months.
If we'd have opted to trial in Oz, instead of the UK, we'd be close to p1 data by now.
Hindsight, eh?
Agree with that Top, particularly about getting a deal.
A major partner would seem the only escape route that Lucy have.
Or the sale of the company, perhaps to a major optical retailer.
I'll wait for the 10-Q...🙄